In a challenging year for ProPhase Labs, now valued at just $10 million in market cap, the company's stock has plummeted to a 52-week low, touching down at $0.41. This significant downturn reflects a ...

In a challenging market environment, ProPhase Labs Inc. (PRPH) stock has touched a 52-week low, dipping to $0.56, marking a ...

Transaction Eliminates More Than $20 Million in Debt, and Other Financial Obligations, Provides $2 million in Cash and Significantly Enhances the ...

ProPhase Labs (PRPH) announced the closing of the sale of its wholly-owned subsidiaries, Pharmaloz Manufacturing Inc. and Pharmaloz Real Estate ...

StockNews.com assumed coverage on shares of ProPhase Labs (NASDAQ:PRPH – Free Report) in a report released on Thursday. The firm issued a sell rating on the stock. ProPhase Labs Stock Performance ...

ProPhase Labs, Inc. is a medical science and technology company, which engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter consumer healthcare ...

Mitosis is conventionally divided into five stages known as prophase, prometaphase, metaphase, anaphase, and telophase. While mitosis is taking place, there is no cell growth and all of the ...

ProPhase Labs shares are trading lower by 50% during Friday's session. The company announced a 4.17 million share offering at 72 cents per share, totaling $3 million.

对于ProPhase Labs来说,这是充满挑战的一年。目前公司市值仅为1000万美元,股价已跌至52周新低,触及0.41美元。这一显著下跌反映出过去一年股价惊人的-91.19%跌幅。根据 InvestingPro 分析,该公司正在快速消耗现金,同时背负着大量债务。投资者担忧地看着ProPhase ...

在充满挑战的市场环境中，ProPhase Labs Inc. (PRPH)股价触及52周新低，跌至0.56美元，与其52周高点7.48美元形成鲜明对比。这一价格水平反映了该公司的严重下滑，过去一年其股价大幅下跌，过去12个月收入下降近80%。投资者目睹了公司市值的急剧缩水，ProPhase ...

Transaction Eliminates More Than $20 Million in Debt, and Other Financial Obligations, Provides $2 million in Cash and Significantly Enhances the Company’s Balance Sheet and Liquidity The ...